References

1. Megace^® ES Prescribing Information. Par Pharmaceutical, Inc. 2006.
2. Data on file. PAR-MES-001. Par Pharmaceutical, Inc.
3. Data on file. PAR-MES-004. Par Pharmaceutical, Inc.
4. Data on file. PAR-MES-006. Par Pharmaceutical, Inc.
5. Data on file. PAR-MES-014. Par Pharmaceutical, Inc.
6. Kotler DP. Cachexia. Ann Intern Med. 2000;133:622-634.
7. IMS NPA Weekly Performance. May 5, 2006.
8. Chapman KM. Loss of appetite: managing unwanted weight loss in the older patient. Geriatrics. 1994;49:54-59.
9. Cella DF, VonRoenn J, Lloyd S, et al. The Bristol-Myers anorexia/cachexia recovery instrument (BACRI): a brief assessment of patients’ subjective response to treatment for anorexia/cachexia. Qual Life Res. 1995;4:221-231.
10. Chang HR, Dulloo AG, Bistrian BR. Role of cytokines in AIDS wasting. Nutrition. 1998;14:853-863.
11. Grinspoon S, Mulligan K. Weight loss and wasting in patients infected with human immunodeficiency virus. Clin Infect Dis. 2003;36(suppl 2):S69-S78.
12. Guidance for Industry Food-Effect Bioavailability and Fed Bioequivalence Studies. Rockville, Md: Food and Drug Administration, Center for Drug Evaluation and Research; December 2002. Available at: http://www.fda.gov/cder/guidance/5194fnl.pdf. Accessed March 17, 2006.
13. Kotler D. Challenges to diagnosis of HIV-associated wasting. J Acquir Immune Defic Syndr. 2004;37:S280-S283.
14. NanoCrystal^® Technology Group. Technology Focus Meeting the Challenges of Drug Delivery. King of Prussia, Pa: Elan Drug Delivery Inc.
15. Oster MH, Enders SR, Samuels SJ, et al. Megestrol acetate in patients with AIDS and cachexia. Ann Intern Med. 1994;121:400-408.
16. Polsky B, Kotler D, Steinhart C. HIV-associated wasting in the HAART era: guidelines for assessment, diagnosis, and treatment. AIDS Patient Care STDs. 2001;15:411-423.
17. Scevola D, Di Matteo A, Uberti F, et al. Reversal of cachexia in patients treated with potent antiretroviral therapy. AIDS Read. 2000;10:365-375.
18. Tang AM, Jacobson DL, Spiegelman D, et al. Increasing risk of 5% or greater unintentional weight loss in a cohort of HIV-infected patients, 1995 to 2003. J Acquir Immune Defic Syndr. 2005;40:70-76.
19. Testa MA, Lenderking WR. The impact of AIDS-associated wasting on quality of life: qualitative issues of measurement and evaluation. J Nutr. 1999;129:282S-289S.
20. Von Roenn JH, Armstrong D, Kotler DP, et al. Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med. 1994;121:393-399.
21. Wanke C, Polsky B, Kotler D. Guidelines for using body composition measurement in patients with human immunodeficiency virus infection. AIDS Patient Care STDs. 2002;16:375-388.
22. Wheeler DA, Gibert CL, Launer CA, et al, and the Terry Beirn Community Programs for Clinical Research on AIDS. Weight loss as a predictor of survival and disease progression in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:80-85.
23. Medical Encyclopedia: weight loss – unintentional. Medline Plus^® Web site. January 24, 2005. Available at: http://www.nlm.nih.gov/medlineplus/ency/article/003107.htm. Accessed November 9, 2006.
24. Electronic orange book approved drug products with therapeutic equivalence evaluations. Food and Drug Administration, Center for Drug Evaluation and Research Web site. January 2007. Available at: http://www.fda.gov/cder/ob/default.htm. Accessed January 11, 2007.
25. Hohman S. Nutrition for HIV/AIDS. Nutrition and Well-Being A to Z Web site. Available at: http://www.faqs.org/nutrition/Hea-Irr/HIV-AIDS.html. Accessed January 11, 2007.
26. Nutrition and weight maintenance. Project Inform, HIV Treatment Information Web site. November 2004. Available at: http://www.projinf.org/fs/nutrition.html. Accessed December 18, 2006.
27. Medical Encyclopedia: weight loss – unintentional. Medline Plus^® Web site. January 24, 2005. Available at: http://www.nlm.nih.gov/medlineplus/ency/article/003107.htm. Accessed November 9, 2006.
28. Kressy J, Wanke C, Gerrior J. Unintentional weight loss/wasting. Tufts University School of Medicine, Nutrition & HIV Research Web site. January 22, 2007. Available at: http://www.tufts.edu/med/nutrition-infection/hiv/health_weight_loss.html. Accessed January 31, 2007.
29. Definition of cachexia. MedicineNet.com, MedTerms Dictionary Web site. Available at: http://www.medterms.com/script/main/art.asp?articlekey=11065. Accessed November 9, 2006.
30. Definition of Lipodystrophy. MedicineNet.com, MedTerms Dictionary Web site. Available at: http://www.medterms.com/script/main/art.asp?articlekey=19803. Accessed December 18, 2006.
31. Medical Encyclopedia: Malnutrition. Medline Plus^® Web site. June 3, 2005. Available at: http://www.nlm.nih.gov/medlineplus/ency/article/000404.htm. Accessed January 11, 2007.
32. Wasting syndrome. AIDS.ORG, Opportunistic Infections and Related Diseases Fact Sheets Web site. February 15, 2006. Available at: http://www.aids.org/Factsheets/519-Wasting-Syndrome.html. Accessed December 18, 2006.
33. Kressy J, Wanke C, Gerrior J. Unintentional weight loss/wasting. Tufts University School of Medicine, Nutrition & HIV Research Web site. January 22, 2007. Available at: http://www.tufts.edu/med/nutrition-infection/hiv/health.html. Accessed January 31, 2007.
34. Wasting Syndrome - Overview. Aidsmap.com. Available at: http://www.aidsmap.com/en/docs/CEFC89BA-7146-4966-8F39-701651DD559D.asp. Accessed February 9, 2007.
35. Understanding unintended weight loss. American Dietetic Association Web site. Available at: http://www.eatright.org/ada/files/Par_Brochure_10_30.pdf. Accessed January 31, 2007.
36. Cilla DD Jr, Gutierrez JL, Femia RA, et al. A pilot study comparing megestrol acetate concentrated suspension (MA-CS) with megestrol acetate oral suspension (MA-OS) on weight gain in patients with HIV-associated unintended weight loss (UWL). Poster presented at: Annual meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; December 17, 2005; Washington, DC. Abstract LB-15.